Explanipedia

Novel Biomarkers for Alcohol-Associated Liver Disease and Their Implications Across Clinical Settings Open

Kaanthi Rama, Vinay Jahagirdar, Francisco Idalsoaga, S. Rhoads, Juan Pablo Arab · 2025

Alcohol-associated liver disease (ALD) is a leading cause of preventable cirrhosis, hepatocellular carcinoma, and liver-related mortality, yet current laboratory and imaging tools detect only late-stage disease. This narrative review synth…

Letter: Refining Mortality Estimates in Severe Alcohol–Associated Hepatitis—Addressing Heterogeneity and Prognostic Assessment. Authors' Reply Open

Francisco Idalsoaga, Luis Antonio Díaz, Mohammad Qasim Khan, Juan Pablo Arab · 2025

Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis Open

Mushfiqur Siddique, Muzzafar Haque, Francisco Idalsoaga, Luis Antonio Díaz, Gene Y. Im , et al. · 2025

Background Severe alcohol‐associated hepatitis (sAH) is a life‐threatening condition. Despite advances in clinical management, prognosis remains poor and long‐term effectiveness of available therapies is uncertain. We conducted a systemati…

EXPLORING THE ROLE OF METABOLIC DYSFUNCTION IN ALCOHOL-ASSOCIATED HEPATITIS: A GLOBAL STUDY Open

María Ignacia Pérez Garayar, Vania Cari Gormaz, Ignacio García Téllez, Francisco Idalsoaga, Gene Y. Im , et al. · 2025

Introduction and Objectives: Severe alcohol-associated hepatitis (AH) carries high mortality. Although the role of cardiometabolic risk factors (CMRF)—including obesity, type 2 diabetes mellitus (T2DM), hypertension (HTN), and dyslipidemia…

EARLY IDENTIFICATION OF LIVER TRANSPLANTATION REQUIREMENT IN ALCOHOL-ASSOCIATED HEPATITIS Open

Luis Antonio Díaz Piga, Francisco Idalsoaga, Gene Y. Im, Bastián Alcayaga, Muzzafar Haque , et al. · 2025

Introduction and Objectives: Severe alcohol‐associated hepatitis (AH) has a high risk of short-term mortality especially in those r with acute‐on‐chronic liver failure (ACLF). Delayed evaluation for liver transplantation (LT) in severe AH …

VALIDATION OF NONINVASIVE CLINICAL PATHWAYS TO IDENTIFY ADVANCED Open

Luis Antonio Díaz Piga, Natalia Baeza, Francisco Idalsoaga, Xiao-Dong Zhou, Ming‐Hua Zheng , et al. · 2025

Introduction and Objectives: Limited data exist on non-invasive clinical algorithms for MetALD and ALD. We aimed to (1) quantify the false-negative rate of standard algorithms combining Fibrosis-4 index (FIB-4) and vibration-controlled tra…

VALIDATION OF AGILE-3+ AND AGILE-4 SCORES FOR NONINVASIVE DETECTION OF FIBROSIS AND CIRRHOSIS IN METABOLIC DYSFUNCTION–ASSOCIATED STEATOTIC LIVER DISEASE IN LATIN AMERICA Open

Carlos Esteban Coronel Castillo, Luis Antonio Díaz Piga, Natalia Baeza, Francisco Idalsoaga, Daniel García , et al. · 2025

Introduction and Objectives: Early detection of liver fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) is crucial for preventing progression to cirrhosis. The Agile-3+ and Agile-4 scores are designed to identify…

ACCELERATED PROGRESSION TO CIRRHOSIS AND HEPATIC DECOMPENSATION IN METALD AND ALD COMPARED TO MASLD: A GLOBAL STUDY Open

Luis Antonio Díaz Piga, Xiaodong Zhou, Natalia Baeza, Francisco Idalsoaga, Gustavo Ayares , et al. · 2025

Introduction and Objectives: The natural history of MetALD remains poorly characterized. In a large global cohort, we compared the natural history of the main steatotic liver disease (SLD) subtypes in terms of liver fibrosis progression an…

LIVER FIBROSIS IN INDIVIDUALS WITH METABOLIC DYSFUNCTION–ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN LATIN AMERICA: INTERIM RESULTS FROM THE STELLA STUDY Open

Luis Antonio Díaz Piga, Francisco Idalsoaga, Mário Guimarães Pessôa, Cláudia P. Oliveira, Patrícia Momoyo Zitelli , et al. · 2025

Introduction and Objectives: Prospective data on liver-fibrosis risk among Latin Americans with MASLD remain scarce, although genetic susceptibility and lifestyle behaviors may heighten vulnerability. This multinational, prospective study …

CHARACTERIZATION OF THE UNRECORDED ALCOHOL USE WORLDWIDE: A SYSTEMATIC REVIEW AND SURVEY-BASED STUDY Open

Katherine Emilia Maldonado Cardona, Hanna Blaney, Deepika Devuni, Muzzafar Haque, Pojsakorn Danpanichkul , et al. · 2025

Introduction and Objectives: Unrecorded alcohol - products that escape taxation, regulation, and safety checks - represents up to one quarter of world alcohol intake and is strongly linked to hazardous drinking and alcohol-related liver di…

Implications of liver fibrosis in clinical trials Open

Vinay Jahagirdar, Kaanthi Rama, Daniel Cabrera, Francisco Idalsoaga, Luis Antonio Díaz , et al. · 2025

Public Health Policies and Strategies to Prevent Alcohol-Related Morbidity and Mortality Open

Roba El Zibaoui, Luis Antonio Díaz, Francisco Idalsoaga, Juan Pablo Arab · 2025

Purpose of Review Alcohol consumption significantly contributes to global morbidity and mortality, particularly in individuals with alcohol-associated liver disease (ALD). This review aims to evaluate the effectiveness of public health pol…

MetALD: New Perspectives on an Old Overlooked Disease Open

Gustavo Ayares, Luis Antonio Díaz, Francisco Idalsoaga, Naim Alkhouri, Mazen Noureddin , et al. · 2025

Metabolic dysfunction‐associated steatotic liver disease (MASLD) and alcohol‐associated liver disease (ALD) are the major contributors to the liver disease burden globally. The rise in these conditions is linked to obesity, type 2 diabetes…

Pentoxifylline use in alcohol-associated hepatitis with acute kidney injury does not improve survival: a global study Open

Francisco Idalsoaga, Luis Antonio Díaz, Winston Dunn, Heer H. Mehta, Vicente Caldentey , et al. · 2025

Background Severe alcohol-associated hepatitis (sAH) is a life-threatening condition with high mortality, where corticosteroid use is the only treatment that has shown short-term benefits. Pentoxifylline, an anti-tumour necrosis factor-alp…

Moderate alcohol-associated hepatitis: A real-world multicenter study Open

Francisco Idalsoaga, Luis Antonio Díaz, Winston Dunn, Heer H. Mehta, Karen E. Muñoz , et al. · 2025

Background: Severe alcohol-associated hepatitis (sAH) is a well-characterized disease with high short-term mortality. However, there is limited research on those with a “less severe condition” (moderate AH). This study aims to characterize…

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis—Authors' Reply Open

Francisco Idalsoaga, Luis Antonio Díaz, Ramón Bataller, Juan Pablo Arab · 2025

Updated recommendations for the management of metabolic dysfunction–associated steatotic liver disease (MASLD) by the Latin American working group Open

Luis Antonio Díaz, Juan Pablo Arab, Francisco Idalsoaga, Javiera Perelli, Javier Andrés Vega , et al. · 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the leading causes of chronic liver disease globally. Based on the 2023 definition, MASLD is characterized by the presence of metabolic dysfunction and limited alco…

Comparison Between Dynamic Models for Predicting Response to Corticosteroids in Alcohol‐Associated Hepatitis: A Global Cohort Study Open

Francisco Idalsoaga, Luis Antonio Díaz, Leonardo Guizzetti, Winston Dunn, Heer H. Mehta , et al. · 2025

Several dynamic models predict mortality and corticosteroid response in alcohol‐associated hepatitis (AH), yet no consensus exists on the most effective model. This study aimed to assess predictive models for corticosteroid response and sh…

Periodontal disease and cirrhosis: current concepts and future prospects Open

David Hudson, Gustavo Ayares, Zahra Taboun, Gurpreet Malhi, Francisco Idalsoaga , et al. · 2025

Periodontal diseases are prevalent among the general population and are associated with several systemic conditions, such as chronic kidney disease and type 2 diabetes mellitus. Chronic liver disease and cirrhosis have also been linked wit…

Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000–2021 Open

Pojsakorn Danpanichkul, Luis Antonio Díaz, Kanokphong Suparan, Primrose Tothanarungroj, Supapitch Sirimangklanurak , et al. · 2025

Background/Aims: Alcohol represents a leading burden of disease worldwide, including alcohol use disorder (AUD) and alcohol-related liver disease (ALD). We aim to assess the global burden of AUD, ALD, and alcohol-attributable primary liver…

Neurogastroenterology and motility disorders in patients with cirrhosis Open

Francisco Idalsoaga, Gustavo Ayares, Hanna Blaney, Daniel Cabrera, Javier Chahuán , et al. · 2025

Neurogastroenterology and motility disorders are complex gastrointestinal conditions that are prevalent worldwide, particularly affecting women and younger individuals. These conditions significantly impact the quality of life of people su…

Characterization of Major Health Consequences of People Experiencing Homelessness in Chile Open

Francisco Idalsoaga, Luis A. Díaz, Freddy Contreras, Oscar Gatica, Josefina Marcenaro , et al. · 2025

P-37 ENHANCED DIAGNOSTIC ACCURACY OF FIB-4 WITH M30 FOR IDENTIFYING AT-RISK PATIENTS WITH STEATOTIC LIVER DISEASE Open

Camila Avilés, Paula Rivera, Nancy Solı́s, Paula Huerta, Jorge Arnold , et al. · 2024

Conflict of interest: No Introduction and Objectives: Liver fibrosis is an important prognostic factor in alcohol-associated liver disease (ALD) and metabolic dysfunction-associated steatohepatitis liver disease (MASLD). New drugs in steat…

O2- CHARACTERIZATION OF STEATOTIC LIVER DISEASE AND THE ROLE OF GENETIC BACKGROUND IN LATIN AMERICA Open

Luis Antonio Díaz Piga, Carolina Aguilera, Gustavo Ayares, Francisco Idalsoaga, Margarita Pizarro , et al. · 2024

Conflict of interest: Yes, FONDECYT #1241450 Introduction and Objectives: Although Latinos living in the United States are at higher risk of steatotic liver disease (SLD), information from Latin American countries is extremely scarce. We a…

OP-5 ACUTE-ON-CHRONIC LIVER FAILURE (ACLF) CRITERIA IN ALCOHOL-ASSOCIATED HEPATITIS: IMPLICATIONS FOR LIVER TRANSPLANTATION Open

Luis Antonio Diaz Piga, Paula Huerta, R.H.A. Farias, Bastián Alcayaga, Francisco Idalsoaga , et al. · 2024

Conflict of interest: No Introduction and Objectives: Background: Severe alcohol-associated hepatitis (AH) is considered a common precipitant of acute-on-chronic liver failure (ACLF). This study aims to characterize the association between…

Challenges in the management of alcohol-associated liver disease in Latin America Open

Francisco Idalsoaga, Luis Antonio Diaz, Gustavo Ayares, Marco Arrese, Juan Pablo Arab · 2024

Disparities in steatosis prevalence in the United States by Race or Ethnicity according to the 2023 criteria Open

Luis Antonio Díaz, Jeffrey V. Lazarus, Eduardo Fuentes‐López, Francisco Idalsoaga, Gustavo Ayares , et al. · 2024

MASLD prevalence is high in the US, especially in men, older individuals, and Hispanics. MetALD and ALD prevalence was substantial but could be underestimated.

Comparative effectiveness of different corticosteroid regimens in severe alcohol-associated hepatitis Open

Alvi H. Islam, Luis Antonio Díaz, Francisco Idalsoaga, Leonardo Guizzetti, Rokhsana Mortuza , et al. · 2024

Letter: Potential impact ofHelicobacter pyloriinfection on oesophageal disorders in chronic liver disease—Authors' reply Open

Francisco Idalsoaga, Luis Antonio Díaz, Gustavo Ayares, Daniel Cabrera, Javier Chahuán , et al. · 2024

LINKED CONTENT This article is linked to Idalsoaga et al papers. To view these articles, visit https://doi.org/10.1111/apt.18193 and https://doi.org/10.1111/apt.18220

Racial and ethnic disparities in the natural history of alcohol‐associated liver disease in the United States Open

Gustavo Ayares, Luis Antonio Díaz, Eduardo Fuentes‐López, Francisco Idalsoaga, Thomas G. Cotter , et al. · 2024

Background Outcomes in alcohol‐associated liver disease (ALD) are influenced by several race and ethnic factors, yet its natural history across the continuum of patients in different stages of the disease is unknown. Methods We conducted a…

Francisco Idalsoaga YOU? Author Swipe